+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Utility of the sendai consensus guidelines for branch-duct intraductal papillary mucinous neoplasms: a systematic review



Utility of the sendai consensus guidelines for branch-duct intraductal papillary mucinous neoplasms: a systematic review



Journal of Gastrointestinal Surgery 18(7): 1350-1357



The Sendai Consensus Guidelines (SCG) was formulated in 2006 to guide the management of intraductal papillary mucinous neoplasms (IPMN). The main area of controversy is the criteria for selection of branch duct (BD)-IPMN for resection. Although these guidelines have gained widespread acceptance, there is limited data to date supporting its use. This systematic review is performed to evaluate the utility of the Sendai Consensus Guidelines (SCG) for BD-IPMN. Studies evaluating the clinical utility of the SCG in surgically resected neoplasms were identified. The SCG were retrospectively applied to all resected neoplasms in these studies. BD-IPMNs which met the criteria for resection were termed SCG+ve and those for surveillance were termed SCG-ve. Twelve studies were included, of which, 9 were suitable for pooled analysis. There were 690 surgically resected BD-IPMNs, of which, 24% were malignant. Five hundred one BD-IPMNs were classified as SCG+ve and 189 were SCG-ve. The positive predictive value (PPV) of SCG+ve neoplasms ranged from 11 to 52% and the NPV of SCG-ve neoplasms ranged from 90 to 100%. Overall, there were 150/501 (29.9%) of malignant BD-IPMNs in the SCG+ve group and 171/189 (90%) of benign BD-IPMNs in the SCG-ve group. Of the 18 reported malignant (11 invasive) BD-IPMNs in the SCG-ve group, 17 (including all 11 invasive) were from a single study. When the results from this single study were excluded, 170/171 (99%) of SCG-ve BD-IPMNs were benign. The results of this review confirm the limitations of the SCG for BD-IPMN. The PPV of the SCG in predicting a malignant BD-IPMN was low and some malignant lesions may be missed based on these guidelines.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056823809

Download citation: RISBibTeXText

PMID: 24668367

DOI: 10.1007/s11605-014-2510-8


Related references

Systematic review of the clinical utility and validity of the Sendai and Fukuoka Consensus Guidelines for the management of intraductal papillary mucinous neoplasms of the pancreas. Hpb 20(6): 497-504, 2018

Validation of the 2012 International Consensus Guidelines Using CT and MRI: Branch Duct and Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgery 266(6): E51-E52, 2017

Validation of international consensus guidelines for the resection of branch duct-type intraductal papillary mucinous neoplasms. British Journal of Surgery 101(6): 686-692, 2014

Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. Journal of the American College of Surgeons 220(2): 243-253, 2015

Risk Factors for Malignancy of Branch-Duct Intraductal Papillary Mucinous Neoplasms: A Critical Evaluation of the Fukuoka Guidelines With a Systematic Review and Meta-analysis. Pancreas 45(9): 1243-1254, 2016

S1297 When to Operate or Observe Branch Duct Intraductal Papillary Mucinous Neoplasms (Ipmn-Br): Evaluation of Consensus Guidelines. Gastroenterology 136(5): A-232, 2009

Single-institution validation of the international consensus guidelines for treatment of branch duct intraductal papillary mucinous neoplasms of the pancreas. Journal of Hepato-Biliary-Pancreatic Surgery 16(3): 353-358, 2009

Accuracy of 2012 International Consensus Guidelines for the prediction of malignancy of branch-duct intraductal papillary mucinous neoplasms of the pancreas. United European Gastroenterology Journal 4(4): 580-586, 2016

Tu1510 Validation of the International Consensus Guidelines for Branch Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Meta-Analysis. Gastroenterology 142(5): S-852-S-853, 2012

Validation of the 2012 International Consensus Guidelines Using Computed Tomography and Magnetic Resonance Imaging: Branch Duct and Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgery 263(3): 557-564, 2016

"High-risk stigmata" of the 2012 international consensus guidelines correlate with the malignant grade of branch duct intraductal papillary mucinous neoplasms of the pancreas. Pancreas 43(8): 1239-1243, 2014

Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Annals of Surgery 258(3): 466-475, 2013

Liberal resection for (presumed) Sendai negative branch-duct intraductal papillary mucinous neoplasms--also not harmless. Annals of Surgery 259(3): E45, 2014

Which guidelines should be used for branch-duct intraductal papillary mucinous neoplasms?. Gastrointestinal Endoscopy 84(3): 446-449, 2016

Incidences of Pancreatic Malignancy and Mortality in Patients With Untreated Branch-Duct Intraductal Papillary Mucinous Neoplasms Undergoing Surveillance: A Systematic Review. Pancreas 46(9): 1098-1110, 2017